"Molecular 
Weight",XLogP3,"Hydrogen Bond 
Donor Count","Hydrogen Bond 
Acceptor Count","Rotatable Bond 
Count","Topological Polar 
Surface Area",Heavy Atom Count,Complexity,pKa,logS,Amount(mg),Type,Amount(mg),Type,Amount(mg),Binder,Amount(mg),Disintegrant,Amount(mg),Disintegrant,Amount(mg),Lubricant,Amount(mg),Lubricant,Amount(mg),Solubilzer,Amount(mg),Disintegration time(s),Reference
265.35,3.3,0,3,0,19.4,20,345,6.67,-2.4,45,1,285,0,0,1,195,1,25,0,0,2,10,0,0,0,0,30,"Formulation studies for mirtazapine orally disintegrating tablets
Drug Development and  Industrial Pharmacy, 2016; 42(6): 1008每1017"
265.35,3.3,0,3,0,19.4,20,345,6.67,-2.4,45,1,188,2,125,1,175,1,25,0,0,2,8.7,0,0,0,0,31,
265.35,3.3,0,3,0,19.4,20,345,6.67,-2.4,45,1,264,0,0,1,195,1,25,0,0,2,10,0,0,0,0,24,
297.74,-0.1,3,7,1,135,17,494,7.9,-2.62,50,3,133.6,0,0,0,0,1,8,2,8,1,15,2,4,0,0,10,"Sucralose as co-crystal co-former for hydrochlorothiazide: development of oral disintegrating tablets
Drug Development and Industrial Pharmacy, 42:8, 1225-1233"
297.74,-0.1,3,7,1,135,17,494,7.9,-2.62,50,0,0,0,0,0,0,1,8,2,8,1,15,2,4,0,0,21,
337.45,-0.6,4,8,7,238,20,469,8.38,-3.1,20,1,75.66,0,0,0,0,3,6.24,0,0,2,0.5,0,0,0,0,17,"Comparative effects of different cellulosic-based directly compressed orodispersable tablets on oral bioavailability of famotidine
Carbohydrate Polymers 77 (2009) 799每806"
337.45,-0.6,4,8,7,238,20,469,8.38,-3.1,20,1,71.76,0,0,0,0,1,2.34,0,0,2,0.5,0,0,0,0,23,
337.45,-0.6,4,8,7,238,20,469,8.38,-3.1,20,4,71.6,0,0,0,0,1,2.34,0,0,2,0.5,0,0,0,0,12,
337.45,-0.6,4,8,7,238,20,469,8.38,-3.1,20,0,0,0,0,0,0,1,2.34,0,0,2,0.5,0,0,0,0,15,
337.45,-0.6,4,8,7,238,20,469,8.38,-3.1,20,4,75.66,0,0,0,0,3,6.24,0,0,2,0.5,0,0,0,0,30,
337.45,-0.6,4,8,7,238,20,469,8.38,-3.1,20,0,0,0,0,0,0,3,6.24,0,0,2,0.5,0,0,0,0,12,
337.45,-0.6,4,8,7,238,20,469,8.38,-3.1,20,1,66.3,0,0,2,11.7,0,0,0,0,2,0.5,0,0,0,0,11,
337.45,-0.6,4,8,7,238,20,469,8.38,-3.1,20,4,66.3,0,0,2,11.7,0,0,0,0,2,0.5,0,0,0,0,47,
337.45,-0.6,4,8,7,238,20,469,8.38,-3.1,20,0,0,0,0,2,11.7,0,0,0,0,2,0.5,0,0,0,0,52,
151.16,0.5,2,2,1,49.3,11,139,9.38,-1.03,224.4,1,303.6,0,0,0,0,1,44.4,0,0,2,3,0,0,0,0,37,"The preparation of orally disintegrating tablets using a hydrophilic waxy binder
International Journal of Pharmaceutics 278 (2004) 423每433"
151.16,0.5,2,2,1,49.3,11,139,9.38,-1.03,224.4,1,303.6,0,0,0,0,1,36.6,0,0,2,3,0,0,0,0,58,
151.16,0.5,2,2,1,49.3,11,139,9.38,-1.03,224.4,1,291.6,0,0,0,0,1,32.4,0,0,2,3,0,0,0,0,40,
151.16,0.5,2,2,1,49.3,11,139,9.38,-1.03,224.4,1,291.6,0,0,0,0,1,32.4,0,0,2,3,0,0,0,0,67,
151.16,0.5,2,2,1,49.3,11,139,9.38,-1.03,325,2,113,0,0,0,0,1,40,3,20,2,2,0,0,0,0,52,"Design, Development and In Vitro Evaluation of Novel Fast Disintegrating Tablet for Acetaminophen Delivery Using Direct Compression Method
Asian Journal of Pharmaceutics ? Oct-Dec 2015 ? 9 (4) | 253"
151.16,0.5,2,2,1,49.3,11,139,9.38,-1.03,325,2,133,0,0,0,0,1,20,0,0,2,2,0,0,0,0,33,
151.16,0.5,2,2,1,49.3,11,139,9.38,-1.03,325,2,113,0,0,0,0,1,40,0,0,2,2,0,0,0,0,35,
151.16,0.5,2,2,1,49.3,11,139,9.38,-1.03,325,2,133,0,0,0,0,3,20,0,0,2,2,0,0,0,0,42,
151.16,0.5,2,2,1,49.3,11,139,9.38,-1.03,325,2,113,0,0,0,0,3,20,0,0,2,2,0,0,0,0,29,
151.16,0.5,2,2,1,49.3,11,139,9.38,-1.03,325,2,113,0,0,0,0,3,40,0,0,2,2,0,0,0,0,37,
151.16,0.5,2,2,1,49.3,11,139,9.38,-1.03,325,2,133,0,0,0,0,1,20,3,20,2,2,0,0,0,0,51,
151.16,0.5,2,2,1,49.3,11,139,9.38,-1.03,325,2,113,0,0,0,0,1,20,3,20,2,2,0,0,0,0,53,
151.16,0.5,2,2,1,49.3,11,139,9.38,-1.03,325,1,30,2,15,2,15,2,15,0,0,2,5,1,5,0,0,7,
312.43,2.8,1,5,1,56.2,22,543,4.01,-3.5,11.8,1,41,2,61.45,0,0,1,14,0,0,2,0.875,1,0.875,1,43,27,"Formulation and In-vitro Evaluation of Orally Disintegrating Tablets of Olanzapine-2-Hydroxypropyl-汕-Cyclodextrin Inclusion Complex
Iranian Journal of Pharmaceutical Research (2010), 9 (4): 335-347"
312.43,2.8,1,5,1,56.2,22,543,4.01,-3.5,11.8,1,41,2,59.7,0,0,1,15.75,0,0,2,0.875,1,0.875,1,43,25,
312.43,2.8,1,5,1,56.2,22,543,4.01,-3.5,11.8,1,41,2,57.95,0,0,1,17.5,0,0,2,0.875,1,0.875,1,43,20,
312.43,2.8,1,5,1,56.2,22,543,4.01,-3.5,11.8,1,41,2,70.2,0,0,1,5.25,0,0,2,0.875,1,0.875,1,43,25,
312.43,2.8,1,5,1,56.2,22,543,4.01,-3.5,11.8,1,41,2,68.45,0,0,1,7,0,0,2,0.875,1,0.875,1,43,25,
312.43,2.8,1,5,1,56.2,22,543,4.01,-3.5,11.8,1,41,2,70.2,0,0,0,0,0,0,2,0.875,1,0.875,1,43,55,
312.43,2.8,1,5,1,56.2,22,543,4.01,-3.5,11.8,1,41,2,68.45,0,0,0,0,0,0,2,0.875,1,0.875,1,43,26,
312.43,2.8,1,5,1,56.2,22,543,4.01,-3.5,11.8,1,41,2,70.2,0,0,1,5.25,0,0,2,0.875,1,0.875,1,43,28,
312.43,2.8,1,5,1,56.2,22,543,4.01,-3.5,11.8,1,41,2,68.45,0,0,1,7,0,0,2,0.875,1,0.875,1,43,21,
312.43,2.8,1,5,1,56.2,22,543,4.01,-3.5,11.8,1,41,2,66.7,0,0,1,8.75,0,0,2,0.875,1,0.875,1,43,22,
312.43,2.8,1,5,1,56.2,22,543,4.01,-3.5,11.8,1,41,2,66.7,0,0,1,8.75,0,0,2,0.875,1,0.875,1,43,15,
312.43,2.8,1,5,1,56.2,22,543,4.01,-3.5,11.8,1,41,2,66.7,0,0,1,8.75,0,0,2,0.875,1,0.875,1,43,68,
296.32,2,1,3,2,72.6,22,440,15.96,-3.4,102,1,150,2,50.08,0,0,2,60,0,0,2,4,0,0,2,109.92,25,"Formulation of cyclodextrin inclusion complex-based orally
disintegrating tablet of eslicarbazepine acetate for improved
oral bioavailability
Materials Science and Engineering C 58 (2016) 826每834"
296.32,2,1,3,2,72.6,22,440,15.96,-3.4,102,1,150,2,70.08,0,0,0,0,0,0,2,4,0,0,2,109.92,49,
296.32,2,1,3,2,72.6,22,440,15.96,-3.4,102,1,150,2,50.08,0,0,0,0,0,0,2,4,0,0,2,109.92,56,
296.32,2,1,3,2,72.6,22,440,15.96,-3.4,102,1,150,2,70.08,0,0,0,0,0,0,2,4,0,0,2,109.92,57,
296.32,2,1,3,2,72.6,22,440,15.96,-3.4,102,1,150,2,50.08,0,0,0,0,0,0,2,4,0,0,2,109.92,59,
296.32,2,1,3,2,72.6,22,440,15.96,-3.4,102,1,150,2,70.08,0,0,1,40,0,0,2,4,0,0,2,109.92,62,
296.32,2,1,3,2,72.6,22,440,15.96,-3.4,102,1,150,2,50.08,0,0,1,60,0,0,2,4,0,0,2,109.92,69,
371.82,2.1,2,7,2,136,23,634,4.22,-3.9,4,1,63.5,2,15,2,3,1,7.5,0,0,2,1,1,1,0,0,7,"Oral disintegrating tablets of analgesic drugs alone and in combination for pain management
Asian Journal of Pharmaceutics ? Oct-Dec 2015 ? 9 (4) | 243"
371.82,2.1,2,7,2,136,23,634,4.22,-3.9,4,1,63.5,2,15,2,3,1,7.5,0,0,2,1,1,1,3,4,7,
371.82,2.1,2,7,2,136,23,634,4.22,-3.9,4,1,63.5,2,15,2,3,1,7.5,0,0,2,1,1,1,3,12.21,7,
416.13,5.3,0,2,6,27,25,417,6.77,-5.7,56.5,1,58,2,58,3,4.7,1,4.8,0,0,3,18,0,0,0,0,40,"Miconazole Nitrate Oral Disintegrating Tablets: In Vivo Performance and Stability Study
AAPS PharmSciTech, Vol. 13, No. 3, September 2012"
416.13,5.3,0,2,6,27,25,417,6.77,-5.7,56.5,1,81,2,41,3,4.7,0,0,0,0,2,6,0,0,0,0,35,
416.13,5.3,0,2,6,27,25,417,6.77,-5.7,56.5,1,58,2,58,3,4.7,1,14.4,0,0,2,6,0,0,0,0,18,
352.31,3.49,1,2,1,12.5,21,370,9.85,-4.5,15,1,10,2,25,0,0,0,0,0,0,0,0,0,0,0,0,27,"Preparation and evaluation of taste-masked dextromethorphan oral disintegrating tablet
Pharmaceutical Development and Technology, 2012; 17(3): 315每320"
352.31,3.49,1,2,1,12.5,21,370,9.85,-4.5,15,1,10,2,25,0,0,0,0,0,0,0,0,0,0,0,0,14,
410.48,2.7,0,6,4,61.9,30,731,8.76,-3.4,0.5,1,1.3,2,2.6,1,0.5,0,0,0,0,1,50,0,0,0,0,13,"Risperidone oral disintegrating mini-tablets: A robust-product for pediatrics
Acta Pharm. 65 (2015) 365每382."
410.48,2.7,0,6,4,61.9,30,731,8.76,-3.4,0.5,1,1.3,2,2.6,0,0,3,0.5,0,0,1,50,0,0,0,0,15,
410.48,2.7,0,6,4,61.9,30,731,8.76,-3.4,0.5,1,2.6,2,1.3,0,0,1,0.5,0,0,1,50,0,0,0,0,3,
410.48,2.7,0,6,4,61.9,30,731,8.76,-3.4,0.5,1,2.6,2,1.3,0,0,3,0.5,0,0,1,50,0,0,0,0,4,
410.48,2.7,0,6,4,61.9,30,731,8.76,-3.4,0.5,1,1.45,2,1.45,0,0,3,0.5,0,0,1,50,0,0,0,0,16,
410.48,2.7,0,6,4,61.9,30,731,8.76,-3.4,0.5,1,2.6,2,1.3,1,0.5,0,0,0,0,1,50,0,0,0,0,2,
410.48,2.7,0,6,4,61.9,30,731,8.76,-3.4,0.5,1,2.6,2,1.3,1,0.5,0,0,0,0,1,50,0,0,0,0,2,
410.48,2.7,0,6,4,61.9,30,731,8.76,-3.4,0.5,1,1.3,2,2.6,0,0,1,0.5,0,0,1,50,0,0,0,0,8,
410.48,2.7,0,6,4,61.9,30,731,8.76,-3.4,0.5,1,1.3,2,2.6,1,0.5,0,0,0,0,1,50,0,0,0,0,4,
410.48,2.7,0,6,4,61.9,30,731,8.76,-3.4,0.5,1,1.45,2,1.45,0,0,0,0,3,0.5,1,50,0,0,0,0,9,
410.48,2.7,0,6,4,61.9,30,731,8.76,-3.4,0.5,1,1.45,2,1.45,1,0.5,0,0,0,0,1,50,0,0,0,0,2,
410.48,2.7,0,6,4,61.9,30,731,8.76,-3.4,0.5,1,1.45,2,1.45,1,0.5,0,0,0,0,1,50,0,0,0,0,3,
410.48,2.7,0,6,4,61.9,30,731,8.76,-3.4,0.5,1,1.45,2,1.45,1,0.5,0,0,0,0,1,50,0,0,0,0,3,
348.87,2.6,2,3,2,50.2,24,442,9,-2.9,50,1,20,2,55,0,0,0,0,3,5,1,2,2,1.5,0,0,35,"Formulation and evaluation of taste mask pellets of granisetron
hydrochloride as oro dispersible tablet
Brazilian Journal of Pharmaceutical Sciences vol. 51, n. 3, jul./sep., 2015"
348.87,2.6,2,3,2,50.2,24,442,9,-2.9,50,1,20,2,52.5,0,0,0,0,3,7.5,1,2,2,1.5,0,0,30,
348.87,2.6,2,3,2,50.2,24,442,9,-2.9,50,1,20,2,55,0,0,1,5,0,0,1,2,2,1.5,0,0,32,
348.87,2.6,2,3,2,50.2,24,442,9,-2.9,50,1,20,2,55,0,0,0,0,0,0,1,2,2,1.5,0,0,28,
348.87,2.6,2,3,2,50.2,24,442,9,-2.9,50,1,20,2,52.5,0,0,0,0,0,0,1,2,2,1.5,0,0,22,
241.29,5.1,2,3,3,49.3,18,292,4.2,-3.78,100,2,81.75,0,0,0,0,2,32.5,0,0,1,32.5,2,3.25,0,0,25,"Mefenamic acid taste-masked oral disintegrating tablets with enhanced solubility via molecular interaction produced by hot melt extrusion technology
Journal of Drug Delivery Science and Technology 27 (2015) 18e27"
241.29,5.1,2,3,3,49.3,18,292,4.2,-3.78,100,2,181.75,0,0,0,0,2,32.5,0,0,1,32.5,2,3.25,0,0,25,
558.64,5,4,6,12,112,41,882,4.33,-6.1,10,1,175,0,0,2,15,1,15,0,0,2,1.2,0,0,0,0,30,"Amorphous solid dispersion with increased gastric solubility in tandem with oral disintegrating tablets: a successful approach to improve the bioavailability of atorvastatin
Pharm Dev Technol, 2015; 20(4): 465每472"
558.64,5,4,6,12,112,41,882,4.33,-6.1,10,1,182.6,0,0,2,15,1,15,0,0,2,1.2,0,0,0,0,30,
608.17,7.9,1,5,12,98.6,42,898,3.12,-7.8,5.2,2,116.8,0,0,0,0,2,6,0,0,2,2,0,0,4,16,15,"Development and Evaluation of Orally Disintegrating
Tablets of Montelukast Sodium by Direct Compression Method
Tropical Journal of Pharmaceutical Research January 2015; 14 (1): 1-6"
608.17,7.9,1,5,12,98.6,42,898,3.12,-7.8,5.2,1,70,2,48.8,0,0,2,20,0,0,2,2,0,0,0,0,40,
608.17,7.9,1,5,12,98.6,42,898,3.12,-7.8,5.2,2,92.41,0,0,0,0,2,4.8,0,0,2,1.596,0,0,4,12.804,8,
608.17,7.9,1,5,12,98.6,42,898,3.12,-7.8,5.2,2,133.08,0,0,0,0,2,6.8,0,0,2,2.261,0,0,4,18.139,35,
608.17,7.9,1,5,12,98.6,42,898,3.12,-7.8,5.2,2,110.79,0,0,0,0,2,6,0,0,2,2,0,0,4,22.005,5,
608.17,7.9,1,5,12,98.6,42,898,3.12,-7.8,5.2,2,116.8,0,0,0,0,2,20,0,0,2,2,0,0,4,16,10,
608.17,7.9,1,5,12,98.6,42,898,3.12,-7.8,5.2,2,113.8,0,0,0,0,2,9,0,0,2,2,0,0,4,16,10,
408.88,3,2,7,10,99.9,28,647,8.79,-4.7,5,1,25,2,40,0,0,2,40,0,0,2,2,0,0,5,1,20,"Coated dextrin microcapsules of amlodipine incorporable into orally disintegrating tablets for geriatric patients
Biomedicine & Pharmacotherapy 68 (2014) 1117每1124"
388.41,3.3,1,7,7,110,28,704,5.32,-4.8,50,1,70,2,58,1,40,1,10,2,10,2,2,0,0,0,0,36,"Fast disintegrating tablets of nisoldipine for intraoral administration
Pharmaceutical Development and Technology, 2014; 19(6): 641每650"
388.41,3.3,1,7,7,110,28,704,5.32,-4.8,50,1,70,2,58,0,0,1,10,2,10,2,2,0,0,0,0,30,
388.41,3.3,1,7,7,110,28,704,5.32,-4.8,50,1,70,2,98,0,0,1,10,2,10,2,2,0,0,0,0,90,
415.95,3.6,1,4,6,38.8,29,510,8.62,-4.9,10,1,170.07,0,0,0,0,0,0,2,56,2,3,0,0,0,0,11,"In vitro and in vivo correlation of disintegration and bitter tastemasking using orally disintegrating tablet containing ion exchangeresin-drug complex
International Journal of Pharmaceutics 455 (2013) 31每 39"
415.95,3.6,1,4,6,38.8,29,510,8.62,-4.9,10,1,198.07,0,0,0,0,0,0,2,28,2,3,0,0,0,0,15,
415.95,3.6,1,4,6,38.8,29,510,8.62,-4.9,10,1,170.07,0,0,0,0,1,56,0,0,2,3,0,0,0,0,7,
415.95,3.6,1,4,6,38.8,29,510,8.62,-4.9,10,1,198.07,0,0,0,0,1,28,0,0,2,3,0,0,0,0,11,
415.95,3.6,1,4,6,38.8,29,510,8.62,-4.9,10,1,170.07,0,0,0,0,0,0,0,0,2,3,0,0,0,0,38,
415.95,3.6,1,4,6,38.8,29,510,8.62,-4.9,10,1,198.07,0,0,0,0,0,0,0,0,2,3,0,0,0,0,73,
256.09,1.4,2,5,1,90.7,16,242,5.7,-2.7,25,1,47.05,0,0,0,0,2,2.5,0,0,2,0.75,0,0,0,0,17,"Orally disintegrating tablet of novel salt of antiepileptic drug:
Formulation strategy and evaluation
European Journal of Pharmaceutics and Biopharmaceutics 85 (2013) 1300每1309"
256.09,1.4,2,5,1,90.7,16,242,5.7,-2.7,25,1,44.25,0,0,0,0,2,5,0,0,2,0.75,0,0,0,0,12,
256.09,1.4,2,5,1,90.7,16,242,5.7,-2.7,25,1,44.25,0,0,0,0,2,5,0,0,2,0.75,0,0,0,0,4,
256.09,1.4,2,5,1,90.7,16,242,5.7,-2.7,25,1,45.25,0,0,0,0,2,3.75,0,0,2,1,0,0,0,0,4,
256.09,1.4,2,5,1,90.7,16,242,5.7,-2.7,25,1,45.75,0,0,0,0,2,3.75,0,0,2,0.5,0,0,0,0,3,
256.09,1.4,2,5,1,90.7,16,242,5.7,-2.7,25,1,56.5,0,0,0,0,2,2.5,0,0,2,1,0,0,0,0,8,
256.09,1.4,2,5,1,90.7,16,242,5.7,-2.7,25,1,44.5,0,0,0,0,2,5,0,0,2,0.5,0,0,0,0,6,
256.09,1.4,2,5,1,90.7,16,242,5.7,-2.7,25,1,45.75,0,0,0,0,2,3.75,0,0,2,0.5,0,0,0,0,11,
256.09,1.4,2,5,1,90.7,16,242,5.7,-2.7,25,1,45.25,0,0,0,0,2,3.75,0,0,2,1,0,0,0,0,17,
256.09,1.4,2,5,1,90.7,16,242,5.7,-2.7,25,1,46.5,0,0,0,0,2,2.5,0,0,2,1,0,0,0,0,8,
256.09,1.4,2,5,1,90.7,16,242,5.7,-2.7,25,1,45.5,0,0,0,0,2,3.75,0,0,2,0.75,0,0,0,0,6,
256.09,1.4,2,5,1,90.7,16,242,5.7,-2.7,25,1,46.5,0,0,0,0,2,2.5,0,0,2,0.75,0,0,0,0,4,
256.09,1.4,2,5,1,90.7,16,242,5.7,-2.7,25,1,45.5,0,0,0,0,2,3.75,0,0,2,0.75,0,0,0,0,8,
326.82,3.2,1,4,1,30.9,23,584,7.5,-3.2,12.5,1,39.9,2,21,0,0,3,11.2,0,0,2,0.7,0,0,1,54.7,15,"Formulation and In Vivo Evaluation of Orally Disintegrating Tablets of Clozapine/Hydroxypropyl-汕-cyclodextrin Inclusion Complexes
PharmSciTech, Vol. 14, No. 2, June 2013"
326.82,3.2,1,4,1,30.9,23,584,7.5,-3.2,12.5,1,94.6,2,21,0,0,3,11.2,0,0,2,0.7,0,0,0,0,15,
299.84,2.4,2,3,4,32.7,20,282,9.41,-2.5,50,1,172,0,0,0,0,2,12,0,0,2,2,1,2,0,0,72,"Taste Masking of Tramadol Hydrochloride by Polymer Carrier System and
Formulation of Rapidly Disintegrating Tablets using Factorial Design
Indian Journal of Pharmaceutical Education and Research Jan-Mar, 2013/ Vol 47/ Issue 1"
299.84,2.4,2,3,4,32.7,20,282,9.41,-2.5,50,1,178,0,0,0,0,2,18,0,0,2,2,1,2,0,0,61,
299.84,2.4,2,3,4,32.7,20,282,9.41,-2.5,50,1,172,0,0,0,0,2,18,0,0,2,2,1,2,0,0,47,
299.84,2.4,2,3,4,32.7,20,282,9.41,-2.5,50,1,166,0,0,0,0,2,18,0,0,2,2,1,2,0,0,34,
474.58,1.5,1,7,7,118,33,838,5.99,-3,29.8,1,236.2,0,0,0,0,2,13,0,0,2,3,0,0,0,0,26,"Development of sildenafil-loaded orally disintegrating tablet with new lactate salt
Drug Development and Industrial Pharmacy,2012; 38(5): 635每641"
474.58,1.5,1,7,7,118,33,838,5.99,-3,29.8,1,251.2,0,0,0,0,2,13,0,0,2,3,0,0,0,0,25,
474.58,1.5,1,7,7,118,33,838,5.99,-3,29.8,1,221.2,0,0,0,0,2,13,0,0,2,3,0,0,0,0,25,
474.58,1.5,1,7,7,118,33,838,5.99,-3,29.8,1,206.2,0,0,0,0,2,13,0,0,2,3,0,0,0,0,26,
474.58,1.5,1,7,7,118,33,838,5.99,-3,29.8,1,205.45,0,0,0,0,2,13,0,0,2,3,1,0.75,0,0,27,
474.58,1.5,1,7,7,118,33,838,5.99,-3,29.8,1,204.7,0,0,0,0,2,13,0,0,2,3,1,1.5,0,0,26,
474.58,1.5,1,7,7,118,33,838,5.99,-3,29.8,1,203.45,0,0,0,0,2,13,0,0,2,3,1,2.25,0,0,27,
293.36,2.3,0,2,2,39.8,22,440,7.34,-3.1,8,1,22.5,2,18.87,0,0,2,3.75,0,0,1,0.75,0,0,0,0,9,"Formulation and In Vivo Evaluation of Ondansetron Orally
Disintegrating Tablets Using Different Superdisintegrants
Arch Pharm Res Vol 34, No 11, 1945-1956, 2011"
293.36,2.3,0,2,2,39.8,22,440,7.34,-3.1,8,1,22.5,2,15.12,0,0,2,7.5,0,0,1,0.75,0,0,0,0,10,
293.36,2.3,0,2,2,39.8,22,440,7.34,-3.1,8,1,22.5,2,11.37,0,0,2,11.25,0,0,1,0.75,0,0,0,0,7,
293.36,2.3,0,2,2,39.8,22,440,7.34,-3.1,8,1,22.5,2,18.87,0,0,2,3.75,0,0,1,0.75,0,0,0,0,6,
293.36,2.3,0,2,2,39.8,22,440,7.34,-3.1,8,1,22.5,2,15.12,0,0,2,7.5,0,0,1,0.75,0,0,0,0,11,
293.36,2.3,0,2,2,39.8,22,440,7.34,-3.1,8,1,22.5,2,11.37,0,0,2,11.25,0,0,1,0.75,0,0,0,0,7,
293.36,2.3,0,2,2,39.8,22,440,7.34,-3.1,8,1,22.5,2,18.87,0,0,2,3.75,0,0,1,0.75,0,0,0,0,7,
293.36,2.3,0,2,2,39.8,22,440,7.34,-3.1,8,1,22.5,2,18.87,0,0,2,3.75,0,0,1,0.75,0,0,0,0,29,
293.36,2.3,0,2,2,39.8,22,440,7.34,-3.1,8,1,22.5,2,15.12,0,0,2,7.5,0,0,1,0.75,0,0,0,0,16,
293.36,2.3,0,2,2,39.8,22,440,7.34,-3.1,8,1,22.5,2,11.37,0,0,2,11.25,0,0,1,0.75,0,0,0,0,26,
293.36,2.3,0,2,2,39.8,22,440,7.34,-3.1,8,1,22.5,2,21.87,0,0,2,0.75,0,0,1,0.75,0,0,0,0,33,
293.36,2.3,0,2,2,39.8,22,440,7.34,-3.1,8,1,22.5,2,20.37,0,0,2,2.25,0,0,1,0.75,0,0,0,0,21,
293.36,2.3,0,2,2,39.8,22,440,7.34,-3.1,8,1,22.5,2,18.87,0,0,2,3.75,0,0,1,0.75,0,0,0,0,15,
293.36,2.3,0,2,2,39.8,22,440,7.34,-3.1,8,1,22.5,2,18.87,0,0,2,3.75,0,0,1,0.75,0,0,0,0,16,
293.36,2.3,0,2,2,39.8,22,440,7.34,-3.1,8,1,22.5,2,17,0,0,2,5.63,0,0,1,0.75,0,0,0,0,14,
351.4,3,2,7,2,136,23,628,4.08,-3.4,7.5,1,20,2,40,0,0,2,10,0,0,2,1,0,0,0,0,46,
318.13,4.51,1,3,4,52.2,20,310,4.15,-4.8,50,2,10,4,131,0,0,0,0,0,0,1,5,2,4,0,0,9,
459.56,4.2,0,6,4,70.6,33,666,4.04,-5.3,100,1,93.75,2,37.5,0,0,1,10,0,0,1,2.5,2,1.25,0,0,70,"Formulation and Evaluation of Rapidly
Disintegrating Fenoverine Tablets: Effect of Superdisintegrants
Drug Development and Industrial Pharmacy"
459.56,4.2,0,6,4,70.6,33,666,4.04,-5.3,100,1,88.75,2,37.5,0,0,1,15,0,0,1,2.5,2,1.25,0,0,55,
459.56,4.2,0,6,4,70.6,33,666,4.04,-5.3,100,1,83.75,2,37.5,0,0,1,20,0,0,1,2.5,2,1.25,0,0,40,
459.56,4.2,0,6,4,70.6,33,666,4.04,-5.3,100,1,93.75,2,37.5,0,0,2,10,0,0,1,2.5,2,1.25,0,0,21,
459.56,4.2,0,6,4,70.6,33,666,4.04,-5.3,100,1,88.75,2,37.5,0,0,2,15,0,0,1,2.5,2,1.25,0,0,19,
459.56,4.2,0,6,4,70.6,33,666,4.04,-5.3,100,1,83.75,2,37.5,0,0,2,20,0,0,1,2.5,2,1.25,0,0,18,
459.56,4.2,0,6,4,70.6,33,666,4.04,-5.3,100,1,93.75,2,37.5,0,0,3,10,0,0,1,2.5,2,1.25,0,0,37,
459.56,4.2,0,6,4,70.6,33,666,4.04,-5.3,100,1,88.75,2,37.5,0,0,3,15,0,0,1,2.5,2,1.25,0,0,30,
459.56,4.2,0,6,4,70.6,33,666,4.04,-5.3,100,1,83.75,2,37.5,0,0,3,20,0,0,1,2.5,2,1.25,0,0,31,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
